| Folate biosynthesis |
1.82 |
9.84e-2 |
23/26 (88.46%) |
ALPL;PTS;AKR1B10;...
|
| N-Glycan biosynthesis |
1.72 |
1.68e-1 |
38/50 (76%) |
FUT8;DAD1;ALG6;...
|
| Malaria |
1.72 |
1.26e-1 |
44/50 (88%) |
TLR4;HBB;VCAM1;...
|
| Various types of N-glycan biosynthesis |
1.70 |
1.19e-1 |
26/39 (66.67%) |
FUT8;DAD1;B4GALT1;...
|
| Pentose and glucuronate interconversions |
1.62 |
1.67e-1 |
17/34 (50%) |
UGDH;AKR1B10;UGT2B17;...
|
| ECM-receptor interaction |
1.62 |
1.39e-1 |
80/88 (90.91%) |
COL6A1;COL4A5;COL4A6;...
|
| African trypanosomiasis |
1.61 |
1.24e-1 |
32/37 (86.49%) |
HBB;VCAM1;SELE;...
|
| Glycine, serine and threonine metabolism |
1.54 |
2.39e-1 |
31/40 (77.5%) |
GATM;GLDC;CBS;...
|
| Mannose type O-glycan biosynthesis |
1.50 |
3.06e-1 |
14/23 (60.87%) |
POMGNT1;B4GALT1;RXYLT1;...
|
| Mineral absorption |
1.48 |
3.02e-1 |
48/60 (80%) |
MT1F;MT2A;MT1G;...
|
| Chagas disease |
1.48 |
2.87e-1 |
93/102 (91.18%) |
TLR4;TGFBR2;TGFB1;...
|
| Glycosaminoglycan biosynthesis |
1.47 |
2.68e-1 |
40/58 (68.97%) |
FUT8;DSE;B4GALT1;...
|
| Protein digestion and absorption |
1.46 |
2.74e-1 |
78/103 (75.73%) |
COL6A1;COL4A5;COL4A6;...
|
| Ubiquinone and other terpenoid-quinone biosynthesis |
1.46 |
2.57e-1 |
9/11 (81.82%) |
NQO1;HPD;GGCX;...
|
| Th17 cell differentiation |
1.45 |
2.67e-1 |
95/107 (88.79%) |
TGFBR2;TGFB1;IL6ST;...
|
| Staphylococcus aureus infection |
1.45 |
2.57e-1 |
72/95 (75.79%) |
KRT17;KRT13;C1QB;...
|
| Linoleic acid metabolism |
1.41 |
3.15e-1 |
21/29 (72.41%) |
PLA2G2A;PLA2G2D;CYP3A4;...
|
| Cysteine and methionine metabolism |
1.41 |
3.17e-1 |
43/50 (86%) |
CBS;PSAT1;GCLM;...
|
| Retinol metabolism |
1.40 |
3.07e-1 |
41/68 (60.29%) |
CYP26A1;UGT2B17;ALDH1A3;...
|
| Estrogen signaling pathway |
1.40 |
2.94e-1 |
119/137 (86.86%) |
HSPA8;KRT17;KRT13;...
|
| Dilated cardiomyopathy |
1.39 |
2.96e-1 |
86/96 (89.58%) |
TGFB1;TPM2;ITGAV;...
|
| Cell adhesion molecules |
1.38 |
3.09e-1 |
118/148 (79.73%) |
CADM1;NLGN4X;CDH2;...
|
| Spliceosome |
1.38 |
3.02e-1 |
101/150 (67.33%) |
HSPA8;PRPF4;LSM3;...
|
| Systemic lupus erythematosus |
1.38 |
2.91e-1 |
45/135 (33.33%) |
C1QB;C1R;C1S;...
|
| Antigen processing and presentation |
1.37 |
2.85e-1 |
60/78 (76.92%) |
HSPA8;HSPA2;CALR;...
|
| Progesterone-mediated oocyte maturation |
1.37 |
2.87e-1 |
75/100 (75%) |
AURKA;CCNB1;PIK3R1;...
|
| Proximal tubule bicarbonate reclamation |
1.36 |
2.97e-1 |
21/23 (91.3%) |
CA2;AQP1;ATP1A2;...
|
| Leishmaniasis |
1.35 |
2.95e-1 |
67/77 (87.01%) |
TLR4;TGFB1;FCGR2C;...
|
| Cell cycle |
1.34 |
3.06e-1 |
110/124 (88.71%) |
CHEK2;CDC20;CCNB1;...
|
| Inflammatory bowel disease |
1.34 |
3.03e-1 |
58/65 (89.23%) |
TLR4;TGFB1;IFNGR1;...
|
| Rheumatoid arthritis |
-1.37 |
3.16e-1 |
78/93 (83.87%) |
MMP1;TNFSF13;ATP6V1E1;...
|
| Breast cancer |
-1.38 |
3.14e-1 |
119/147 (80.95%) |
CDKN1A;SOS1;CSNK1A1;...
|
| Primary bile acid biosynthesis |
-1.38 |
3.24e-1 |
15/17 (88.24%) |
BAAT;CYP39A1;CYP7A1;...
|
| Chemokine signaling pathway |
-1.39 |
3.21e-1 |
163/192 (84.9%) |
CCL22;RASGRP2;RAC3;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
-1.39 |
3.27e-1 |
5/5 (100%) |
HK3;HKDC1;HK2
|
| Epithelial cell signaling in Helicobacter pylori infect... |
-1.39 |
3.30e-1 |
62/70 (88.57%) |
ADAM10;ATP6V1G1;PLCG1;...
|
| Basal cell carcinoma |
-1.40 |
3.34e-1 |
41/63 (65.08%) |
FZD4;GLI3;TP53;...
|
| Viral myocarditis |
-1.42 |
2.91e-1 |
53/60 (88.33%) |
RAC3;ITGB2;DMD;...
|
| TNF signaling pathway |
-1.45 |
2.43e-1 |
103/112 (91.96%) |
TRADD;CASP7;TNFRSF1B;...
|
| Insulin signaling pathway |
-1.46 |
2.34e-1 |
121/137 (88.32%) |
LIPE;EIF4E2;ACACB;...
|
| Human cytomegalovirus infection |
-1.46 |
2.41e-1 |
201/225 (89.33%) |
RAC3;CREB5;PTK2B;...
|
| MicroRNAs in cancer |
-1.47 |
2.45e-1 |
146/310 (47.1%) |
PIM1;DNMT3A;EFNA3;...
|
| Non-alcoholic fatty liver disease |
-1.48 |
2.33e-1 |
126/155 (81.29%) |
NDUFC1;COX8A;INSR;...
|
| Phototransduction |
-1.48 |
2.36e-1 |
21/29 (72.41%) |
CALML3;CNGB1;GNAT1;...
|
| Legionellosis |
-1.49 |
2.45e-1 |
51/57 (89.47%) |
CXCL1;ARF1;ITGAM;...
|
| Herpes simplex virus 1 infection |
-1.49 |
2.47e-1 |
165/498 (33.13%) |
EIF4EBP1;TP53;SP100;...
|
| Epstein-Barr virus infection |
-1.51 |
2.36e-1 |
189/202 (93.56%) |
STAT1;CDKN1A;TRADD;...
|
| PPAR signaling pathway |
-1.53 |
2.14e-1 |
66/74 (89.19%) |
APOA2;CYP7A1;PDPK1;...
|
| Glycerolipid metabolism |
-1.54 |
2.24e-1 |
44/61 (72.13%) |
MGLL;AGK;TKFC;...
|
| Tyrosine metabolism |
-1.56 |
2.05e-1 |
30/36 (83.33%) |
TPO;ADH1B;AOC3;...
|
| Hepatitis C |
-1.58 |
1.95e-1 |
139/157 (88.54%) |
CLDN15;CLDN3;STAT1;...
|
| IL-17 signaling pathway |
-1.58 |
2.14e-1 |
84/94 (89.36%) |
MAPK7;MMP1;ANAPC5;...
|
| Fatty acid biosynthesis |
-1.59 |
2.24e-1 |
16/18 (88.89%) |
ACSBG2;HSD17B8;MECR;...
|
| Fatty acid degradation |
-1.59 |
2.30e-1 |
40/43 (93.02%) |
HADHA;ADH1B;ACADVL;...
|
| Adipocytokine signaling pathway |
-1.65 |
1.53e-1 |
64/69 (92.75%) |
PRKAB1;TRADD;LEP;...
|
| Cholesterol metabolism |
-1.65 |
1.84e-1 |
44/50 (88%) |
MYLIP;LDLR;ANGPTL4;...
|
| Thyroid cancer |
-1.68 |
1.70e-1 |
36/37 (97.3%) |
TP53;BAX;CDKN1A;...
|
| NOD-like receptor signaling pathway |
-1.72 |
1.55e-1 |
145/181 (80.11%) |
BCL2L1;BRCC3;STAT1;...
|
| Bladder cancer |
-1.73 |
2.27e-1 |
40/41 (97.56%) |
THBS1;TP53;CDKN1A;...
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.77 |
2.51e-1 |
172/193 (89.12%) |
STAT1;CDKN1A;PLCG1;...
|
